Report of Foreign Issuer (6-k)
October 16 2017 - 6:07AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 6-K
Report of Foreign Private Issuer
Pursuant to Rule 13a-16 or 15d-16
under the Securities Exchange Act of 1934
For the month of: October 2017
Commission file number: 001-36578
BIOBLAST PHARMA LTD.
(Translation of registrant’s name
into English)
37 Dereh Menechem Begin St., 15
th
Floor
Tel Aviv 6522042 Israel
(Address of principal executive offices)
Indicate by check mark whether the registrant files or will
file annual reports under cover of Form 20-F or Form 40-F.
Form
20-F
x
Form
40-F
¨
Indicate by check mark if the registrant is submitting the Form
6-K in paper as permitted by Regulations S-T Rule 101(b)(1):_____
Indicate by check mark if the registrant is submitting the Form
6-K in paper as permitted by Regulations S-T Rule 101(b)(7):_____
Bioblast Regains Compliance with NASDAQ
Minimum Bid Price Requirement
On October 10, 2017, Bioblast Pharma Ltd. (the “Company”)
received a letter from The NASDAQ Stock Market (“NASDAQ”) stating that it has regained compliance with the minimum
bid price requirement for continued listing on The NASDAQ Capital Market.
The Company had previously announced that it had received notice
from NASDAQ that the bid price of its ordinary shares was below $1.00 per share for 30 consecutive business days and, as a result,
the Company was not in compliance with Listing Rule 5550(a)(2). The Company was provided with 180 days, or until October 9, 2017,
to regain compliance with Listing Rule 5550(a)(2).
After the Company effected a 5 to 1 reverse split of its share
capital on September 25, 2017, NASDAQ determined that for 10 consecutive business days from the date of the reverse split, the
closing bid price of the Company’s ordinary shares was $1.00 per share or greater. Accordingly, NASDAQ informed the Company
that it has regained compliance with Listing Rule 5550(a)(2) and this matter is now closed.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act
of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
|
Bioblast Pharma Ltd.
|
|
(Registrant)
|
|
|
|
|
By:
|
/s/ Fredric
Price
|
|
Name:
|
Fredric Price
|
|
|
Executive Chairman
|
Date: October 16, 2017
Bioblast Pharma Ltd. (NASDAQ:ORPN)
Historical Stock Chart
From Aug 2024 to Sep 2024
Bioblast Pharma Ltd. (NASDAQ:ORPN)
Historical Stock Chart
From Sep 2023 to Sep 2024